Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors

被引:540
作者
Lee, S
Jilani, SM
Nikolova, GV
Carpizo, D
Iruela-Arispe, ML [1 ]
机构
[1] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
D O I
10.1083/jcb.200409115
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Vascular endothelial growth factor ( VEGF) is a critical mediator of blood vessel formation during development and in pathological conditions. In this study, we demonstrate that VEGF bioavailability is regulated extracellularly by matrix metalloproteinases ( MMPs) through intramolecular processing. Specifically, we show that a subset of MMPs can cleave matrix-bound isoforms of VEGF, releasing soluble fragments. We have mapped the region of MMP processing, have generated recombinant forms that mimic MMP- cleaved and MMP-resistant VEGF, and have explored their biological impact in tumors. Although all forms induced similar VEGF receptor 2 phosphorylation levels, the angiogenic outcomes were distinct. MMP-cleaved VEGF promoted the capillary dilation of existent vessels but mediated a marginal neovascular response within the tumor. In contrast, MMP-resistant VEGF supported extensive growth of thin vessels with multiple and frequent branch points. Our findings support the view that matrix-bound VEGF and nontethered VEGF provide different signaling outcomes. These findings reveal a novel aspect in the regulation of extracellular VEGF that holds significance for vascular patterning.
引用
收藏
页码:681 / 691
页数:11
相关论文
共 51 条
  • [11] VEGF: an update on biological and therapeutic aspects
    Farrara, N
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2000, 11 (06) : 617 - 624
  • [12] VEGF and the quest for tumour angiogenesis factors
    Ferrara, N
    [J]. NATURE REVIEWS CANCER, 2002, 2 (10) : 795 - 803
  • [13] Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    Ferrara, N
    Hillan, KJ
    Gerber, HP
    Novotny, W
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) : 391 - 400
  • [14] The biology of VEGF and its receptors
    Ferrara, N
    Gerber, HP
    LeCouter, J
    [J]. NATURE MEDICINE, 2003, 9 (06) : 669 - 676
  • [15] Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    Ferrara, N
    CarverMoore, K
    Chen, H
    Dowd, M
    Lu, L
    OShea, KS
    PowellBraxton, L
    Hillan, KJ
    Moore, MW
    [J]. NATURE, 1996, 380 (6573) : 439 - 442
  • [16] Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex
    Fuentes-Prior, P
    Iwanaga, Y
    Huber, R
    Pagila, R
    Rumennik, G
    Seto, M
    Morser, J
    Light, DR
    Bode, W
    [J]. NATURE, 2000, 404 (6777) : 518 - 525
  • [17] Gerber HP, 1999, DEVELOPMENT, V126, P1149
  • [18] VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    Gerber, HP
    Malik, AK
    Solar, GP
    Sherman, D
    Liang, XH
    Meng, G
    Hong, K
    Marsters, JC
    Ferrara, N
    [J]. NATURE, 2002, 417 (6892) : 954 - 958
  • [19] Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature
    Grunstein, J
    Masbad, JJ
    Hickey, R
    Giordano, F
    Johnson, RS
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (19) : 7282 - 7291
  • [20] Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin
    Hamano, Y
    Zeisberg, M
    Sugimoto, H
    Lively, JC
    Maeshima, Y
    Yang, CQ
    Hynes, RO
    Werb, Z
    Sudhakar, A
    Kalluri, R
    [J]. CANCER CELL, 2003, 3 (06) : 589 - 601